Clinical Trial Update: Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy [Phase 2]

View source ↗

Summary

This Phase 2 trial investigated the combination of pralatrexate and docetaxel in patients with Stage IV esophageal or gastroesophageal cancer who had failed pla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Status: COMPLETED | Results posted: 2015-10-16